Which has better earnings and valuation, RADX or ENGN?

Radiopharm Theranostics has higher revenue and earnings than enGene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 13.45 -$37.43M N/A N/A enGene N/A N/A -$117.30M -$1.13 N/A

Is RADX or ENGN more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A enGene N/A -27.97% -22.65%

Does the media favor RADX or ENGN?

In the previous week, enGene had 14 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 17 mentions for enGene and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.74 beat enGene's score of 0.19 indicating that Radiopharm Theranostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 2 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, RADX or RANI?

Rani Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 13.45 -$37.43M N/A N/A Rani Therapeutics $1.63M 73.72 -$29.67M -$0.27 N/A

Is RADX or RANI more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Rani Therapeutics N/A -104.60% -65.17%

Which has higher earnings & valuation, RADX or BDTX?

Black Diamond Therapeutics has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 13.45 -$37.43M N/A N/A Black Diamond Therapeutics $70M 1.61 $22.37M -$0.75 N/A

Is RADX or BDTX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Black Diamond Therapeutics N/A -32.10% -25.21%

Which has better earnings & valuation, RADX or GNLX?

Genelux has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 13.45 -$37.43M N/A N/A Genelux $10K 11,445.72 -$32.15M -$0.86 N/A

Is RADX or GNLX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Genelux N/A -205.85% -138.79%

Does the media prefer RADX or GNLX?

In the previous week, Radiopharm Theranostics and Radiopharm Theranostics both had 3 articles in the media. Genelux's average media sentiment score of 1.20 beat Radiopharm Theranostics' score of 0.74 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, RADX or COYA?

Coya Therapeutics has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 13.45 -$37.43M N/A N/A Coya Therapeutics $7.95M 14.43 -$21.23M -$1.07 N/A

Does the media refer more to RADX or COYA?

In the previous week, Coya Therapeutics had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 7 mentions for Coya Therapeutics and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.74 beat Coya Therapeutics' score of 0.28 indicating that Radiopharm Theranostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Radiopharm Theranostics (RADX) Competitors

$1.75 +0.02 (+1.10%)

Closing price 09/18/2026 03:56 PM Eastern

Extended Trading

$1.71 -0.04 (-2.23%)

As of 09/18/2026 07:30 PM Eastern

Compare

RADX vs. ENGN, RANI, BDTX, GNLX, and COYA

Should you buy Radiopharm Theranostics stock or one of its competitors? Radiopharm Theranostics's main competitors and comparable companies include enGene (ENGN), Rani Therapeutics (RANI), Black Diamond Therapeutics (BDTX), Genelux (GNLX), and Coya Therapeutics (COYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Radiopharm Theranostics compare to enGene?

Radiopharm Theranostics (NASDAQ:RADX) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

In the previous week, enGene had 14 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 17 mentions for enGene and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.74 beat enGene's score of 0.19 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	2 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Radiopharm Theranostics' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
enGene	N/A	-27.97%	-22.65%

Radiopharm Theranostics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market.

64.2% of enGene shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Radiopharm Theranostics has higher revenue and earnings than enGene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	13.45	-$37.43M	N/A	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 528.93%. enGene has a consensus price target of $11.05, indicating a potential upside of 478.30%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Radiopharm Theranostics beats enGene on 8 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Rani Therapeutics?

Radiopharm Theranostics (NASDAQ:RADX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Rani Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	13.45	-$37.43M	N/A	N/A
Rani Therapeutics	$1.63M	73.72	-$29.67M	-$0.27	N/A

In the previous week, Radiopharm Theranostics had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 0 mentions for Rani Therapeutics. Radiopharm Theranostics' average media sentiment score of 0.74 beat Rani Therapeutics' score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Overall Sentiment
Radiopharm Theranostics	Positive
Rani Therapeutics	Neutral

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Radiopharm Theranostics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Rani Therapeutics	N/A	-104.60%	-65.17%

Radiopharm Theranostics presently has a consensus price target of $11.00, suggesting a potential upside of 528.93%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 915.08%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Radiopharm Theranostics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Summary

Rani Therapeutics beats Radiopharm Theranostics on 8 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Black Diamond Therapeutics?

Radiopharm Theranostics (NASDAQ:RADX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Radiopharm Theranostics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Black Diamond Therapeutics has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	13.45	-$37.43M	N/A	N/A
Black Diamond Therapeutics	$70M	1.61	$22.37M	-$0.75	N/A

Radiopharm Theranostics presently has a consensus price target of $11.00, suggesting a potential upside of 528.93%. Black Diamond Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 422.96%. Given Radiopharm Theranostics' higher possible upside, research analysts plainly believe Radiopharm Theranostics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Radiopharm Theranostics had 3 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 0 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Radiopharm Theranostics' score of 0.74 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Positive
Black Diamond Therapeutics	Positive

Radiopharm Theranostics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Radiopharm Theranostics on 8 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Genelux?

Radiopharm Theranostics (NASDAQ:RADX) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Radiopharm Theranostics and Radiopharm Theranostics both had 3 articles in the media. Genelux's average media sentiment score of 1.20 beat Radiopharm Theranostics' score of 0.74 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	13.45	-$37.43M	N/A	N/A
Genelux	$10K	11,445.72	-$32.15M	-$0.86	N/A

37.3% of Genelux shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Radiopharm Theranostics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Genelux	N/A	-205.85%	-138.79%

Radiopharm Theranostics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Genelux has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Radiopharm Theranostics presently has a consensus price target of $11.00, indicating a potential upside of 528.93%. Genelux has a consensus price target of $18.00, indicating a potential upside of 611.46%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Genelux beats Radiopharm Theranostics on 9 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Coya Therapeutics?

Radiopharm Theranostics (NASDAQ:RADX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

39.8% of Coya Therapeutics shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Coya Therapeutics had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 7 mentions for Coya Therapeutics and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.74 beat Coya Therapeutics' score of 0.28 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	13.45	-$37.43M	N/A	N/A
Coya Therapeutics	$7.95M	14.43	-$21.23M	-$1.07	N/A

Radiopharm Theranostics presently has a consensus target price of $11.00, indicating a potential upside of 528.93%. Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 213.57%. Given Radiopharm Theranostics' higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Radiopharm Theranostics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Radiopharm Theranostics' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Radiopharm Theranostics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Coya Therapeutics beats Radiopharm Theranostics on 8 of the 14 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.86M	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	N/A	14.23	275.49	25.40
Price / Sales	13.45	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.37	15.45	10.46	6.33
Net Income	-$37.43M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-11.67%	-1.21%	0.59%	1.12%
1 Month Performance	-23.62%	-3.29%	-1.74%	-2.39%
1 Year Performance	-73.05%	37.74%	18.13%	5.35%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	2.7288 of 5 stars	$1.75 +1.1%	$11.00 +528.9%	-73.1%	$23.86M	$1.88M	N/A	14
ENGN enGene	3.9297 of 5 stars	$1.80 +1.7%	$11.05 +513.6%	-72.0%	$118.56M	N/A	N/A	31
RANI Rani Therapeutics	3.2618 of 5 stars	$0.84 +2.5%	$8.75 +938.5%	+67.4%	$114.58M	$1.63M	N/A	110
BDTX Black Diamond Therapeutics	2.9394 of 5 stars	$1.98 +1.0%	$10.25 +417.7%	-40.2%	$112.61M	N/A	N/A	90
GNLX Genelux	2.5554 of 5 stars	$2.49 +0.4%	$18.00 +622.9%	-39.2%	$112.21M	$10K	N/A	10	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. ENGN, RANI, BDTX, GNLX, and COYA

How does Radiopharm Theranostics compare to enGene?

Summary

How does Radiopharm Theranostics compare to Rani Therapeutics?

Summary

How does Radiopharm Theranostics compare to Black Diamond Therapeutics?

Summary

How does Radiopharm Theranostics compare to Genelux?

Summary

How does Radiopharm Theranostics compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. ENGN, RANI, BDTX, GNLX, and COYA

How does Radiopharm Theranostics compare to enGene?

Does the media favor RADX or ENGN?

Is RADX or ENGN more profitable?

Which has more volatility & risk, RADX or ENGN?

Do institutionals & insiders believe in RADX or ENGN?

Which has better earnings and valuation, RADX or ENGN?

Do analysts prefer RADX or ENGN?

Summary

How does Radiopharm Theranostics compare to Rani Therapeutics?

Which has stronger valuation and earnings, RADX or RANI?

Does the media prefer RADX or RANI?

Do insiders & institutionals have more ownership in RADX or RANI?

Is RADX or RANI more profitable?

Do analysts recommend RADX or RANI?

Which has more volatility and risk, RADX or RANI?

Summary

How does Radiopharm Theranostics compare to Black Diamond Therapeutics?

Is RADX or BDTX more profitable?

Do insiders and institutionals hold more shares of RADX or BDTX?

Which has higher earnings & valuation, RADX or BDTX?

Do analysts prefer RADX or BDTX?

Does the media refer more to RADX or BDTX?

Which has more risk & volatility, RADX or BDTX?

Summary

How does Radiopharm Theranostics compare to Genelux?

Does the media prefer RADX or GNLX?

Which has better earnings & valuation, RADX or GNLX?

Do insiders & institutionals believe in RADX or GNLX?

Is RADX or GNLX more profitable?

Which has more volatility and risk, RADX or GNLX?

Do analysts recommend RADX or GNLX?

Summary

How does Radiopharm Theranostics compare to Coya Therapeutics?

Do institutionals and insiders believe in RADX or COYA?

Does the media refer more to RADX or COYA?

Which has higher earnings and valuation, RADX or COYA?

Do analysts prefer RADX or COYA?

Is RADX or COYA more profitable?

Which has more volatility and risk, RADX or COYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools